Skip to content
Axcess News – Lifestyle
Author:
Calidi Biotherapeutics, Inc
Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
April 1, 2026
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights
March 27, 2026
The top burger restaurant chains in America
March 27, 2026
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
March 24, 2026
Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
March 12, 2026
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
March 9, 2026
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
March 7, 2026
Calidi Biotherapeutics Announces Proposed Public Offering
March 7, 2026
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
March 5, 2026
←
Previous Page
1
2
3